key: cord-1000774-vr3w5o3d
authors: Henderson, Lorna R.; McShane, Helen; Kiparoglou, Vasiliki
title: Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre
date: 2022-02-19
journal: Health Res Policy Syst
DOI: 10.1186/s12961-022-00827-0
sha: 80ec43d24320755d6d3ba2e1b667ead365aac2ca
doc_id: 1000774
cord_uid: vr3w5o3d

With over 5 million COVID-19 deaths at the time of writing, the response of research leaders was and is critical to developing treatments to control the global pandemic. As clinical research leaders urgently repurposed existing research programmes and resources towards the COVID-19 pandemic, there is an opportunity to reflect on practices observed in Biomedical Research Centre (BRC) settings. BRCs are partnerships between leading National Health Service organizations and universities in England conducting translational research for patient benefit funded by the National Institute for Health Research (NIHR). Oxford BRC-supported researchers have led the rapid set-up of numerous COVID-19 research studies at record speed with global impact. However, the specific contribution of BRCs to the COVID-19 pandemic in the literature is sparse. Firstly, we reflect on the strategic work of clinical research leaders, creating resilient NIHR research infrastructure to facilitate rapid COVID-19 research. Secondly, we discuss how COVID-19 rapid research exemplars supported by Oxford BRC illustrate “capacity”, “readiness” and “capability” at an organizational and individual level to respond to the global pandemic. Rapid response research in turbulent environments requires strategic organizational leadership to create resilient infrastructure and resources. The rapid research exemplars from the Oxford BRC illustrate capability and capacity at an organizational and individual level in a dynamic environment to respond during the COVID-19 public health challenge. This response was underpinned by swift adaptation and repurposing of existing research resources and expertise by the Oxford BRC to deliver rapid research to address different aspects of COVID-19.

With over 5 million COVID-19 deaths at the time of writing, the response of research leaders was and is critical to developing treatments to control the global pandemic [1] . As clinical research leaders have urgently repurposed existing research programmes and resources towards the COVID-19 pandemic, there is an opportunity to reflect on practices observed in Biomedical Research Centre (BRC) settings. BRCs are partnerships between leading National Health Service (NHS) organizations and universities in England conducting translational research for patient benefit funded by the National Institute for Health Research (NIHR) [2, 3] Secondly, we discuss how COVID-19 rapid research exemplars supported by Oxford BRC illustrate "capacity", "readiness" and "capability" at an organizational and individual level to respond to the global pandemic.

BRCs were established in 2007, bringing world-leading NHS clinicians and university academics together to conduct "translational research", developing groundbreaking treatments for patient benefit as well as the NHS [2] . There are now 20 BRCs, and this source of funding enables supported researchers to develop innovative research but also to attract external investment contributing to the health and wealth of the nation [2] .

During the COVID-19 pandemic, BRC researchers have been at the forefront of the rapid research response, exemplified by the development and testing of vaccines and early-phase drug trial at record speed [4]. Reflecting back, Professor Dame Sally Davies' strategic leadership as the "architect" of the NIHR in 2006 created strong research infrastructure and significant funding (> £1 billion annual budget), securing the United Kingdom's reputation as a world leader in clinical research [10] [11] [12] . The foresight in creating this translational research funding and infrastructure enabled an agile response in times of crisis, including the development of an effective vaccine against SARS-CoV-2 [2-4, 7, 10-12] . This new source of funding catalysed significant expansion in the capacity and capability of translational research and the establishment of BRCs [2, 10] . The importance of research funding and infrastructure to respond to the COVID-19 pandemic is recognized, including the role of the United Kingdom Clinical Research Networks in rapid study setup and recruitment [8, 9, 13] . Comparisons between the Canadian clinical research system and the United Kingdom NIHR underline the importance of not only adequate research funding but, crucially, integration with the NHS to facilitate agile response to crises [13] .

Oxford BRC is a partnership between Oxford University Hospitals NHS Foundation Trust, which has an international reputation for clinical research, and the University of Oxford, currently ranked as the world's best institution for medical teaching and research [14, 15] . The Oxford BRC supports world-leading NHS clinicians and academics across 20 research themes (Fig. 1) [4] . It was well placed to deliver rapid COVID-19 research, as it is characterized by partnership working: many of the researchers are practising clinicians providing direct care to patients and the public, alongside their academic work. Furthermore, Oxford BRC research is fully integrated with Oxford's hospitals, ensuring medical innovations can be moved quickly "from bench to bedside", out of laboratories into clinical trials and onto the NHS care setting [4].

Here we illustrate how the Oxford BRC supported a rapid response into COVID-19 research, demonstrating "capacity", "readiness" and "capability" at an organizational and research leadership level in a dynamic environment [4, 16] . At the beginning of the pandemic, Oxford BRC research funding was quickly reallocated to "pump-prime" emerging high-impact COVID-19-related research, including the Oxford/AstraZeneca (AZ) COVID-19 vaccine and the RECOVERY trial [7, 17, 18] . Over 1 year later, Oxford BRC has supported over 100 COVID-19 projects, 34 of which were Urgent Public Health (UPH) research studies nationally prioritized by NIHR [19] . COVID-19 rapid research required agile, collaborative leadership behaviour but also innovative highperforming teams who can quickly adapt and implement complex research at speed [4, 7] . This is illustrated in our Vaccines Theme with the development of the Oxford/AZ SARS-CoV-2 vaccine.

Oxford BRC provided crucial early funding to expedite the development of the COVID-19 vaccine work led by the Vaccines Theme researchers and then contributed to a clinical trial to evaluate the safety of the vaccine [4, 7] . The Vaccines Theme researchers used their expertise and existing BRC-funded infrastructure to rapidly develop a vaccine for SARS-CoV-2. When the SARS-CoV-2 virus emerged in China at the end of 2019, Vaccines Theme researchers were already working on human coronavirus vaccines and were therefore in a unique position to respond rapidly to the pandemic. Professor Andrew Pollard, co-Theme Lead for the Vaccines Theme, led the phase III testing of this vaccine candidate across 19 trial sites in the United Kingdom, South Africa and Brazil. Work to develop this vaccine first began in January 2020, and the vaccine was approved in January 2021 at unprecedented speed [17] .

Funding from the Oxford BRC and others contributed to the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial, providing evidence about potential treatments for those hospitalized with COVID-19 or suspected COVID- 19 [18, 20] . The trial was led by Professor Peter Horby and Professor Martin Landray, Theme Lead for the Clinical Informatics and Big Data cross-cutting 

The rapid research exemplars from the Oxford BRC illustrate capability and capacity at an organizational and individual level in a dynamic environment to respond during the COVID-19 public health challenge [4, 7, 16] . This response was underpinned by swift adaptation and repurposing of existing research resources and expertise by the Oxford BRC to deliver rapid research to address different aspects of COVID- 19 [4, 7] . Rapid response research in turbulent environments requires strategic organizational leadership to create resilient infrastructure and resources.

World Health Organization coronavirus disease (COVID 19) pandemic outbreak situation

Experimental medicine

About us. In: Department of Health and Social Care

Oxford's COVID-19 research receives government funding

Ten minutes with Professor Helen McShane, Director, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust

Lessons from the pandemic on the value of clinical research infrastructure

Impacts of COVID-19 on clinical research in the UK: a Multimethod qualitative case study

10 years of the UK's National Institute for Health Research

NIHR's response to COVID 19

Integrating research into clinical practice: challenges and solutions for Canada

Oxford named best for medicine for ninth consecutive year

Designing organisations for dynamic capabilities

University of Oxford COVID 19 Oxford Vaccine Trial covid19vaccinetrial. co.uk

NIHR Urgent Public Health COVID-19 studies

RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

The authors gratefully acknowledge Dr Anthony Berendt for his contributions to initial discussions around the concept of the paper.

Authors' contributions LH conceived the article and wrote the first draft; all other authors contributed to further drafts and editing. All authors read and approved the final manuscript.

The authors are supported by the National Institute for Health Research Oxford Biomedical Research Centre. The views expressed are those of the 

Data sharing is not applicable to this article as no datasets were generated or analysed.

Ethics approval and consent to participate This was not applicable as the study did not involve human participants.

This is not applicable as the manuscript does not contain any individual person's data in any form.

The authors declare that they have no competing interests.Author details 1 National Institute for Health Research Oxford Biomedical Research Centre,